BusinessHorizon Pharma plc Announces Availability of PROCYSBI™ (cysteamine bitartrate) in CanadaBy Nasdaq OMXOct 26, 2017, 12:01 PM UTC
BusinessHorizon Pharma plc Announces Four Poster Presentations on PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Capsules at Cystinosis Research Network 2017 Family ConferenceBy Nasdaq OMXJul 14, 2017, 12:00 PM UTC
BusinessRaptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International CongressBy Nasdaq OMXAug 24, 2016, 11:30 AM UTC
BusinessRaptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled LevofloxacinBy Nasdaq OMXMar 16, 2016, 11:30 AM UTC
BusinessRaptor Pharmaceutical to Participate in International Rare Disease Week Through Multiple Patient Advocacy ActivitiesBy Nasdaq OMXFeb 29, 2016, 12:30 PM UTC
BusinessRaptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate UpdateBy Nasdaq OMXFeb 25, 2016, 9:05 PM UTC
BusinessRaptor Pharmaceutical to Hold Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25, 2016, at 4:30 p.m. ETBy Nasdaq OMXFeb 18, 2016, 12:30 PM UTC
BusinessFour New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan ExclusivityBy Nasdaq OMXJan 25, 2016, 12:05 PM UTC
